Applied Nutrition PLC APN
LSE · United Kingdom · Health Technology
GBp 267.50-6.50 (-2.37%)
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Step into a supermarket and you could be forgiven for thinking you had wandered into a gym bro’s fever dream.
For Applied Nutrition’s 2027 fiscal year, revenue and adjusted EBITDA are forecast to be above current consensus but higher whey protein costs are expected to hit margins.
The sports nutrition group lifted guidance after sales jumped 50%, but rising whey costs mean next year’s gains may come with thinner margins.
The health and wellness brand now expects annual underlying earnings to jump by 40% to around £43.3 million after sales soared to £160 million.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.